• HEK293 lysate (10ug protein in RIPA buffer) overexpressing Human SLAMF8 with C-terminal MYC tag probed with STJ72416 (0. 01ug/ml) in Lane A and probed with anti-MYC Tag (1/1000) in lane C. Mock-transfected HEK293 probed with STJ72416 (0. 01ug/ml) in Lane B. Primary incubations were for 1 hour. Detected by chemiluminescence.

Anti-SLAMF8 antibody (C-Term) (STJ72416)

SKU:
STJ72416-100

Shipping:
Free Shipping
Current Stock:
Host: Goat
Applications: Pep-ELISA/WB-Trf/IHC
Reactivity: Human
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Goat polyclonal antibody anti-SLAMF8 (C-Term) is suitable for use in ELISA, Western Blot and Immunohistochemistry research applications.
Clonality: Polyclonal
Conjugation: Unconjugated
Isotype: IgG
Formulation: 0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin. NA
Purification: Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.
Concentration: 0.5 mg/mL
Dilution Range: IHC-5µg/ml
ELISA-antibody detection limit dilution 1:32000.
Storage Instruction: Store at-20°C on receipt and minimise freeze-thaw cycles.
Gene Symbol: SLAMF8
Gene ID: 56833
Uniprot ID: SLAF8_HUMAN
Immunogen Region: C-Term
Accession Number: NP_064510.1
Immunogen Sequence: HADRVGPETENP
Function May play a role in B-lineage commitment and/or modulation of signaling through the B-cell receptor.
Protein Name Slam Family Member 8
B-Lymphocyte Activator Macrophage Expressed
Bcm-Like Membrane Protein
Cd Antigen Cd353
Cellular Localisation Membrane
Single-Pass Type I Membrane Protein
Alternative Antibody Names Anti-Slam Family Member 8 antibody
Anti-B-Lymphocyte Activator Macrophage Expressed antibody
Anti-Bcm-Like Membrane Protein antibody
Anti-Cd Antigen Cd353 antibody
Anti-SLAMF8 antibody
Anti-BLAME antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance